Ultragenyx Pharmaceutical (RARE) Expected to Announce Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is expected to issue its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.32) per share and revenue of $158.71 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $43.58 on Wednesday. The firm has a market capitalization of $4.02 billion, a PE ratio of -6.74 and a beta of 0.60. The business’s 50-day moving average is $43.94 and its two-hundred day moving average is $49.65. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 8,273 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. This trade represents a 0.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on RARE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. TD Cowen lifted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wedbush reissued a “neutral” rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Piper Sandler raised their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. dropped their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $92.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.